Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms
About this trial
This is an interventional treatment trial for Advanced Solid Tumor focused on measuring Nectin-4, Solid tumor, Transitional urothelial carcinoma, Renal insufficiency
Eligibility Criteria
Key Inclusion Criteria
- Life expectancy ≥12 weeks
- Must have exhausted all standard treatment options, including appropriate targeted therapies, for example, EGFR or ALK therapies for relevant oncogene driver NSCLC patients; or available MMAE-containing ADC treatment in urothelial carcinoma; or patients for which no standard therapy is considered appropriate or to provide clinical benefit, as assessed by the Investigator.
Part A cohorts: Patients with the following tumor histology:
- patients with advanced, histologically confirmed urothelial (transitional cell) carcinoma that recurred after or has been refractory to prior therapy (fresh tumor biopsy or an archived sample must be submitted); or
- Patients with advanced, histologically confirmed pancreatic, breast, non-small-cell lung cancer (NSCLC), gastric, esophageal, head and neck, or ovarian tumor that recurred after or has been refractory to prior therapy (fresh tumor biopsy or an archived sample testing positive for Nectin-4 expression)
- Part B-1 and B-2 Nectin-4 basket monotherapy and combination cohorts: patients with solid tumor advanced, recurrent disease confirmed as Nectin-4 positive who must have failed at least one prior line of therapy and radiologically progressed on most recent line of therapy.
- Part C renal insufficiency cohort: Patients with solid tumor, advanced disease who have renal insufficiency.
Key Exclusion Criteria (all patients)
- Clinically relevant troponin elevation
- Uncontrolled diabetes
- Uncontrolled, symptomatic brain metastases
- Patients with uncontrolled hypertension
- History of another malignancy within 3 years before first dose of BT8009 or residual disease from a previously diagnosed malignancy (with some exceptions).
- Systemic IV anti-infective treatment, or fever within the last 14 days prior to first dose of BT8009.
Parts A-2 and B-2 Nivolumab Combination Cohorts Exclusion Criteria
- Prior organ transplant (including allogeneic)
- Active systemic infection requiring therapy
- History of interstitial lung disease
Other protocol-defined Inclusion/Exclusion criteria may apply
Sites / Locations
- Sarah Cannon Research Institute at HealthONERecruiting
- Ocala Oncology CenterRecruiting
- Advent HealthRecruiting
- Horizon Oncology Research
- Norton Cancer Institute, Downtown
- Comprehensive Cancer Centers of Nevada
- Icahn School of Medicine at Mount SinaiRecruiting
- University Hospitals Cleveland Medical CenterRecruiting
- Thomas Jefferson University, Sidney Kimmel Cancer CenterRecruiting
- Tennessee Oncology, PLLCRecruiting
- Mary Crowley Cancer Research CenterRecruiting
- The University of Texas MD Anderson Cancer CenterRecruiting
- Cross Cancer InstituteRecruiting
- University Health Network, Princess Margaret Cancer CentreRecruiting
- Institut BergonieRecruiting
- Centre Leon BerardRecruiting
- Institut Paoli-CalmettesRecruiting
- Centre Eugene MarquisRecruiting
- Institut Gustave RoussyRecruiting
- Ospedale San RaffaeleRecruiting
- Vall d'Hebron Institute of OncologyRecruiting
- Hospital Clinic de BarcelonaRecruiting
- START Madrid Fundacion Jimenez DiazRecruiting
- Next Oncology - Hospital Quironsalud MadridRecruiting
- Sarah Cannon Research Institute UKRecruiting
- The Christie NHS Foundation TrustRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm 10
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Part A-1 -BT8009 Monotherapy Dose Escalation
Part A-2 -BT8009 in Combination with Pembrolizumab Dose De-Escalation
Cohort B-1 - BT8009 Monotherapy Dose Expansion
Cohort B-2- BT8009 Monotherapy Dose Expansion
Cohort B-3- BT8009 Monotherapy Dose Expansion
Cohort B-4- BT8009 Monotherapy Dose Expansion
Cohort B-5- BT8009 Monotherapy Dose Expansion
Cohort B-6- BT8009 Monotherapy Dose Expansion
Cohort B-7- BT8009 in Combination with Pembrolizumab Dose Expansion
Part C - Renal Insufficiency BT8009 Monotherapy Dose Expansion
Escalating doses of BT8009 via IV
Participants will receive BT8009 and a standard dose of pembrolizumab.
Participants will receive a selected dose of BT8009.
Participants will receive a selected dose of BT8009.
Participants will receive a selected dose of BT8009. .
Participants will receive a selected dose of BT8009.
Participants will receive a selected dose of BT8009.
Participants will receive a selected dose of BT8009.
Participants will receive a selected dose of BT8009 and standard dose of pembrolizumab.
Participants will receive a selected dose of BT8009.